Executive – Manufacturing Quality Compliance
- Process Development and Manufacturing
- Full-time
- Hyderabad, IN
Posted on March 18, 2025
PopVax is an Indian full-stack biotechnology company developing novel mRNA vaccines and therapeutics using computational protein design. Our first vaccine is a next-generation COVID-19 booster, which will enter a first-in-human Phase I clinical trial in the U.S. early next year – this vaccine is intended to broaden protection against both current and predicted future SARS-CoV-2 variants, reducing the possibility of a new mutation in the virus suddenly causing another massive wave of infection. We have a preclinical pipeline of 6 additional novel vaccine candidates built on our mRNA-LNP platform that we will be taking into clinical trials over the next few years. Our work to date has been funded primarily via project agreements totalling 10+ million USD with the Bill & Melinda Gates Foundation and Vitalik Buterin's public health & biosecurity organization Balvi.
We have built and operationalized a small-scale GMP-capable mRNA foundry in Hyderabad to produce clinical doses for this trial, as well as others in our pipeline. We are looking to hire a new member for our Process Development & Manufacturing team to help adapt cutting-edge technologies from the lab to the rigors of a cGMP-compliant production process.
All candidates must possess:
A master’s or bachelor’s degree in pharmaceutical sciences, biology, biotechnology, or any other life sciences field.
Proficiency in communicating and drafting documents such as SOPs, QMS documentation, protocols, and reports in formal English.
Strong applied mathematical skills, including basic statistical analysis.
A proactive learning attitude with high attention to detail.
Ability to manage multiple documentation tasks accurately and efficiently.
The ideal candidate will possess:
A minimum of 1 year of documentation experience in a cGMP environment within vaccines or other biologics is preferred. Specific experience with nucleic acid or nanoparticle-based products would be a significant advantage.
In-depth understanding of cGMP requirements and regulations, along with the core principles underlying them. Experience in drafting GMP SOPs, batch manufacturing records (BMRs), production reports, and other related documents.
Strong knowledge of pharmaceutical QMS principles, with direct experience in handling and documenting deviations, change control, CAPA, OOS, and OOT investigations.
Role Responsibilities:
Ensure that all manufacturing documentation activities comply with regulatory requirements, including Schedule M (India), ICH guidelines, US FDA cGMP, and other relevant standards.
Implement and maintain quality systems and procedures to ensure the accuracy, consistency, and compliance of documentation.
Continuously evaluate documentation processes to identify areas for improvement and develop strategies to enhance efficiency and quality.
Develop, execute, and document validation protocols in accordance with QA requirements. Prepare validation reports, investigation reports, root cause analyses, and conclusions.
Prepare, review, and update SOPs to enhance manufacturing and quality documentation systems.
Manage and document deviations, change controls, Corrective and Preventive Actions (CAPA), Out-of-Specification (OOS), and Out-of-Trend (OOT) investigations.
Collaborate with Quality Assurance, Regulatory Affairs, and other departments to ensure accurate documentation supports product development, regulatory submissions, and business objectives.
Actively participate in internal and external audits by providing necessary documentation and ensuring compliance with regulatory expectations.
Apply basic statistical analysis to support investigations and reporting within the QMS documentation framework.
We offer very competitive compensation, comprehensive health insurance covering immediate family (including pre-existing conditions), and, most importantly, a collaborative work environment focused on solving the cutting-edge multidisciplinary challenges of our novel mRNA platform.